Evidence map›Paper›PMID 41107978›Full record

ReviewClinical epigenetics2025

Comprehensive regulation of γ-globin expression by epigenetic modifications and protein post-translational modifications.

Dahang Ye, Meihuan Chen, Ying Zhu, XinYuan Feng, Liangpu Xu, Hailong Huang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Dahang Ye *Medical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China.
Meihuan Chen *Medical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China.
Ying ZhuMedical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China.
XinYuan FengMedical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China.
Liangpu XuMedical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China.
Hailong HuangMedical Genetic Diagnosis and Therapy Center of Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fujian Provincial Key Laboratory of Prenatal Diagnosis and Birth Defect, 18 Dagshan Road, Fuzhou, 350001, China. huanghailong@fjmu.edu.cn.

Funding

Fujian Provincial Natural Science Foundation of China No. 2023J011217Joint Funds for the Innovation of Science and Technology of Fujian provinc No. 2021Y9173, 2021Y9174 and 2023Y9364National Natural Science Foundation of China No. 81970170the Major Scientific Research Program for Young and Middle-aged Health Professionals of Fujian Province 2023ZQNZD009
6 · The paper itself

Abstract

As a member of the hemoglobin family, γ-globin is usually persistently expressed at high levels to perform the oxygen-carrying function during fetal development. In recent years, related gene editing clinical trials have confirmed that reactivation of γ-globin expression is a promising therapeutic strategy for treating β-hemoglobinopathies, including β-thalassemia and sickle cell disease. Human γ-globin expression is finely regulated by multiple mechanisms, and a deeper understanding of the mechanisms will help develop drugs that target its activation. With the advancement of biotechnology, epigenetic modifications (EMs) and protein post-translational modifications (PPTMs) have shown irreplaceable roles in the regulation of γ-globin expression. Therefore, this review will comprehensively summarize the regulatory mechanisms of EMs and PPTMs on γ-globin to provide new ideas for the treatment of β-hemoglobinopathies.

Indexed as

Epigenesis, Geneticgamma-GlobinsProtein Processing, Post-TranslationalAnemia, Sickle Cellbeta-ThalassemiaDNA MethylationGene EditingHumansgamma-GlobinsEpigenetic modificationsProtein post-translational modificationsRegulatory mechanismsβ-hemoglobinopathiesγ-globin

Identifiers

PMID41107978
PMCPMC12535125

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.